1

**[Effect of Hormone Replacement Therapy on Lupus Activity](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02013416/full" \t "_blank)**

NCT00392093

https://clinicaltrials.gov/show/NCT00392093, **2006** | added to CENTRAL: 31 January 2020 | 2020 Issue 01

CT.gov

2

[**Vasomotor hot flashes and cardiac repolarization: a randomized placebo-controlled trial of postmenopausal hormone therapy**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01622149/full)

H Lantto, P Haapalahti, M Viitasalo, H Väänänen, ARA Sovijärvi, O Ylikorkala, TS Mikkola

Menopause (New York, N.Y.), **2017**, 24(12), 1386‐1391 | added to CENTRAL: 31 August 2018 | 2018 Issue 8

PubMed

3

[**Vasomotor hot flashes and cardiac repolarization: a randomized placebo-controlled trial of postmenopausal hormone therapy**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01395589/full)

H Lantto, P Haapalahti, M Viitasalo, H Vaananen, ARA Sovijarvi, O Ylikorkala, TS Mikkola

Menopause (New York, N.Y.), **2017**, 24(12), 1386‐1391 | added to CENTRAL: 31 August 2017 | 2017 Issue 8

PubMed Embase

4

[**Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01490495/full)

NCT01958073

https://clinicaltrials.gov/show/NCT01958073, **2013** | added to CENTRAL: 31 May 2018 | 2018 Issue 5

CT.gov

5

[**Oestrogen levels in serum and urine of premenopausal women eating low and high amounts of meat**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01087349/full)

BE Harmon, Y Morimoto, F Beckford, AA Franke, FZ Stanczyk, G Maskarinec

Public health nutrition, **2014**, 17(9), 2087‐2093 | added to CENTRAL: 31 October 2015 | 2015 Issue 10

PubMed

6

[**A hormonal therapy for menopausal women with MS: a phase Ib/IIa randomized controlled trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02404561/full)

R Bove, A Anderson, W Rowles, KA Rankin, NK Hills, M Carleton, J Cooper, BAC Cree, JM Gelfand, JS Graves, RG Henry, KM Krysko, G Rush, SS Zamvil, H Joffe, JR Chan, AJ Green

Multiple sclerosis and related disorders, **2022**, 61, 103747 | added to CENTRAL: 30 June 2022 | 2022 Issue 06

PubMed

7

[**A hormonal therapy for menopausal women with MS: a phase Ib/IIa randomized controlled trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02388533/full)

R Bove, A Anderson, W Rowles, KA Rankin, NK Hills, M Carleton, J Cooper, BAC Cree, JM Gelfand, JS Graves, RG Henry, KM Krysko, G Rush, SS Zamvil, H Joffe, JR Chan, AJ Green

Multiple sclerosis and related disorders, **2022**, 61, 103747 | added to CENTRAL: 30 April 2022 | 2022 Issue 04

PubMed Embase

8

[**Estrogen can modulate menopausal women's heart rate variability**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01047446/full)

SG Yang, M Mlček, O Kittnar

Physiological research, **2013**, 62(Suppl 1), S165‐71 | added to CENTRAL: 31 March 2015 | 2015 Issue 3

PubMed

9

[**Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02321455/full)

B-K Yoon, J Sung, Y-M Song, S-M Kim, K-A Son, JH Yoo, S-J Park, D-K Kim

Clinical hypertension, **2021**, 27(1) | added to CENTRAL: 31 October 2021 | 2021 Issue 10

Embase

10

[**Association between menopausal hormone therapy and incidence of psoriasis: a secondary analysis from the Women's Health Initiative randomized clinical trials**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02299222/full)

AA Chan, J Noguti, CT Yang, SR Feldman, RB Wallace, AH Shadyab, JE Manson, AK Aragaki, RT Chlebowski, DJ Lee

British journal of dermatology, **2021**, 185(3), 669‐671 | added to CENTRAL: 31 August 2021 | 2021 Issue 08

PubMed Embase

11

[**Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02638470/full)

BK Yoon, J Sung, YM Song, SM Kim, KA Son, JH Yoo, SJ Park, DK Kim

Clinical hypertension, **2021**, 27(1), 18 | added to CENTRAL: 31 January 2024 | 2024 Issue 1

PubMed

12

[**24P Letrozole and exemestane as serum estrogen suppressors during neoadjuvant therapy in breast cancer patients: a head-to-head comparison**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02706396/full)

J Geisler, B Almas, K Fjermeros, K Viste, SB Geisler, T Sauer, K Selsas, B-E Bertelsen

ESMO open, **2024**, 9 | added to CENTRAL: 30 June 2024 | 2024 Issue 6

Embase

13

[**Effects of estrogen and progesterone on neuroactive steroids and cytokines in patients with suicidality**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02601646/full)

JC Barone, E Wenzel, V Alluri, D Moriarity, G Pinna, E Walsh, DR Rubinow, AL Morrow, TA Eisenlohr-Moul

Psychoneuroendocrinology, **2023**, 157, 106359 | added to CENTRAL: 31 October 2023 | 2023 Issue 10

PubMed

14

[**The fase II study evaluates the safety and efficacy of treatment with low doses of topical vaginal estrogen in pre- and postmenopausal patients with breast cancer and urogenital symptoms related to adjuvant hormone therapy**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01808202/full)

EUCTR2010-024603-26-IT

https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2010-024603-26-IT, **2012** | added to CENTRAL: 31 March 2019 | 2019 Issue 3

ICTRP

15

[**heredERA Breast Cancer: phase iii study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC9545) for estrogen receptor+, HER2+ advanced breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02537648/full)

S Kuemmel, C Harper-Wynne, YH Park, F Franke, M De Laurentiis, E Schumacher-Wulf, D Eiger, S Heeson, M Shivhare, E Restuccia, J O'Shaughnessy

Cancer research, **2023**, 83(5) | added to CENTRAL: 30 April 2023 | 2023 Issue 4

Embase

16

[**lidERA Breast Cancer: a phase iii adjuvant study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy in patients with estrogen receptor+, HER2- early breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02537651/full)

P Schmid, CE Geyer, N Harbeck, M Rimawi, S Hurvitz, M Martin, S Loi, S Saji, K Hae Jung, G Werutsky, DL Stroyakovsky, V Lopez-Valverde, M Davis, T Badovinac Crnjevic, PD Perez-Moreno, A Bardia

Cancer research, **2023**, 83(5) | added to CENTRAL: 30 April 2023 | 2023 Issue 4

Embase

17

[**evERA Breast Cancer: a phase iii study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2- locally advanced or metastatic breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02537642/full)

EL Mayer, S Tolaney, AM Brufsky, W Gradishar, K Jhaveri, M Martin, L Moscetti, G Vidal, P Cortazar, M Feldman, B-M Day, H Rugo

Cancer research, **2023**, 83(5) | added to CENTRAL: 30 April 2023 | 2023 Issue 4

Embase

18

[**Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01792780/full)

JM Dempsey, KM Kidwell, CL Gersch, Z Desta, AM Storniolo, V Stearns, TC Skaar, DF Hayes, NL Henry, JM Rae, DL Hertz

Journal of clinical oncology, **2018**, 36(15) | added to CENTRAL: 31 March 2019 | 2019 Issue 3

Embase

19

[**PD10-05 Neoadjuvant tamoxifen therapy reactivates tumor suppressor protein p53 in luminal breast cancer patients: results from a window-of-opportunity clinical trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02570807/full)

GM Das, SA Kulkarni, C Oturkar, S Rosario, SB Edge, J Wang, WM Swetzig, AD Hutson, B Kaipparettu, A Groman, A Adjei, AK Goey, CD Morrison, S Kumar

Cancer research, **2023**, 83(5) | added to CENTRAL: 30 June 2023 | 2023 Issue 6

Embase

20

[**206TiP Randomized, multicenter, international phase III ARTEST study to evaluate enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients who previously received an estrogen-blocking agent and a CDK 4/6 inhibitor**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02396296/full)

A Brufsky, H Linden, HS Rugo, C Vogel, J O'Shaughnessy, RH Getzenberg, KG Barnette, D Rodriguez, MS Steiner, E Mayer

Annals of oncology, **2022**, 33, S221 | added to CENTRAL: 31 May 2022 | 2022 Issue 05

Embase

21

[**Changes in visual evoked potentials during the menstrual cycle in young women**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02772374/full)

S Rekha

National journal of physiology, pharmacy and pharmacology, **2024**, 14(10), 2067‐2070 | added to CENTRAL: 30 November 2024 | 2024 Issue 11

Embase

22

[**The therapeutic role and potential mechanism of EGCG in obesity-related precocious puberty as determined by integrated metabolomics and network pharmacology**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02573506/full)

Q Gu, L Xia, Q Du, Y Shao, J He, P Wu, L Liang, X Shen

Frontiers in endocrinology, **2023**, 14, 1159657 | added to CENTRAL: 30 June 2023 | 2023 Issue 6

PubMed

23

[**The treatment of hyperhomocysteinemia**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01779678/full)

BA Maron, J Loscalzo

Annual review of medicine, **2009**, 60, 39‐54 | added to CENTRAL: 31 March 2019 | 2019 Issue 3

PubMed Embase

24

[**The WinPro study: a window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01937291/full)

E Carson, D Segara, A Parker, S O'Toole, A Coates, B Mann, G Lindeman, W Tilley, E Lim

Cancer research, **2019**, 79(4) | added to CENTRAL: 30 June 2019 | 2019 Issue 06

Embase

25

[**A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01128391/full)

K Tryfonidis, G Basaran, J Bogaerts, M Debled, L Dirix, JC Thery, VC Tjan-Heijnen, D Van den Weyngaert, T Cufer, M Piccart, D Cameron

European journal of cancer (Oxford, England : 1990), **2016**, 53, 144‐154 | added to CENTRAL: 29 February 2016 | 2016 Issue 2

PubMed Embase

26

[**Hormonal therapy for menopausal women with MS: a phase II RCT**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02215138/full)

A Anderson, W Rowles, G Rush, M Carleton, N Hills, J Cooper, BA Cree, JM Gelfand, J Graves, KM Krysko, T West, S Zamvil, A Green, R Bove

Multiple sclerosis journal, **2020**, 26(1 SUPPL), 45 | added to CENTRAL: 31 January 2021 | 2021 Issue 01

Embase

27

[**Effect of oral hormone therapy on the degree of oxidative stress in postmenopausal women with metabolic syndrome**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01078183/full)

M Sanchez-Rodriguez, M Zacarias-Flores, E Correa-Munoz, VM Mendoza-Nunez

Menopause (New York, N.Y.), **2014**, 21(12), 1366‐1367 | added to CENTRAL: 31 August 2015 | 2015 Issue 8

Embase

28

[**The WinPro study: awindow of opportunity study of endocrine therapy with and without prometrium in postmenopausalwomen with early stage hormone receptor-positive breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01669353/full)

E Lim, E Carson

Asia-Pacific journal of clinical oncology, **2018**, 14(Supplement 7), 194‐195 | added to CENTRAL: 31 January 2019 | 2019 Issue 1

Embase

29

[**THE USE OF DYDROGESTERONE TO PREVENT LH PEAK IN RANDOM-START OVARIAN STIMULATION FOR FERTILITY PRESERVATION**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02193175/full)

M Braham, K Kacem, Z Zemni, S Amari, W Jaafar, S Chtourou, M Hamdoun, L Debbabi, N Chakroun, O Bahri, F Zhioua, A Fadhlaoui

Fertility and sterility, **2020**, 114(3), e226‐e227 | added to CENTRAL: 30 November 2020 | 2020 Issue 11

Embase

30

[**Dynamic metabolic response of prostate cancer patients treated with ADT and low carb diet**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01980865/full)

S Freedland, P-H Lin, EY Chen, V Tolstikov, J-T Chi, R Sarangarajan, NR Narain, MA Kiebish

Cancer research, **2019**, 79(13) | added to CENTRAL: 30 September 2019 | 2019 Issue 09

Embase

31

[**Bisphenol A exposures and hormone concentrations in a cohort of women receiving aromatase inhibitor therapy for breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02472129/full)

K Robien, MN Kirstein, PA Pawloski, AC Shapiro

Journal of clinical oncology, **2022**, 40(16) | added to CENTRAL: 31 October 2022 | 2022 Issue 10

Embase

32

[**Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02203578/full)

H Wadstrom, A Pettersson, K Ekstrom Smedby, J Askling

Annals of the rheumatic diseases, **2020**, 79(SUPPL 1), 81 | added to CENTRAL: 31 December 2020 | 2020 Issue 12

Embase

33

[**Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01460677/full)

G Viale, FA de Snoo, L Slaets, J Bogaerts, L van 't Veer, EJ Rutgers, MJ Piccart-Gebhart, L Stork-Sloots, A Glas, L Russo, P Dell'Orto, K Tryfonidis, S Litière, F Cardoso

Breast cancer research and treatment, **2018**, 167(1), 123‐131 | added to CENTRAL: 30 April 2018 | 2018 Issue 4

PubMed Embase

34

[**Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01939314/full)

H Johansson, V Aristarco, S Gandini, J Gjerde, D Macis, A Guerrieri-Gonzaga, D Serrano, M Lazzeroni, A Rajasekaran, CV Williard, G Mellgren, A DeCensi, B Bonanni

Pharmacogenomics journal, **2020**, 20(1), 19‐26 | added to CENTRAL: 30 June 2019 | 2019 Issue 06

PubMed Embase

35

[**Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02737671/full)

D Serrano, H Johansson, B-E Bertelsen, S Gandini, G Mellgren, P Thomas, KD Crew, NB Kumar, D Macis, V Aristarco, A Guerrieri-Gonzaga, M Lazzeroni, M D'Amico, T Buttiron-Webber, IM Briata, S Spinaci, V Galimberti, LA Vornik, E Villar-Sanchez, PH Brown, BM Heckman-Stoddard, E Szabo, B Bonanni, A Decensi

Journal of the National Cancer Institute, **2024** | added to CENTRAL: 31 August 2024 | 2024 Issue 8

PubMed Embase

36

[**Urinary enterolactone is associated with plasma proteins related to immunity and cancer development in healthy participants on controlled diets**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02291935/full)

FL Miles, SL Navarro, CB Garrison, TW Randolph, Y Zhang, A Shojaie, M Kratz, MAJ Hullar, D Raftery, ML Neuhouser, PD Lampe, JW Lampe

Human nutrition and metabolism, **2021**, 25 | added to CENTRAL: 31 August 2021 | 2021 Issue 08

Embase

37

[**First generation aromatase inhibitors--aminoglutethimide and testololactone**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01781997/full)

G Cocconi

Breast cancer research and treatment, **1994**, 30(1), 57‐80 | added to CENTRAL: 31 March 2019 | 2019 Issue 3

PubMed Embase

38

[**LBA21 Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02769070/full)

RF Salgado, A Bardia, G Curigliano, X Hu, RA Dent, J-Y Pierga, J Tsurutani, H Wildiers, GRR Ricciardi, C Marchio, F Penault-Llorca, C Bor-Angelier, A Andrzejuk-Cwik, A Darilay, T Matsuo, R Shami, F Jones, G Viale

Annals of oncology, **2024**, 35, S1213‐S1214 | added to CENTRAL: 30 November 2024 | 2024 Issue 11

Embase

39

[**A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate (ALN) on bone mineral density (BMD) and bone turnover in perimenopausal women with low BMD**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01267359/full)

AA Khan, S Dubois, OA Khan, MZ Rahman, C Derzko

Endocrine reviews, **2014**, 35(no pagination) | added to CENTRAL: 28 February 2017 | 2017 Issue 2

Embase

40

[**Impact of Sex Hormones, Postmenopausal Hormone Therapy and Risk Factors on Development of Abdominal Aortic Aneurysm in Women: a Population-based Prospective Study in Norway: a Hunt Study**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02052720/full)

LA Nyronning, V Videm, PR Romundstad, R Hultgren, E Mattsson

European journal of vascular and endovascular surgery, **2019**, 58(6), e219 | added to CENTRAL: 31 January 2020 | 2020 Issue 01

Embase

41

[**The Natural Substance MS-10 Improves and Prevents Menopausal Symptoms, Including Colpoxerosis, in Clinical Research**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01259753/full)

YH Noh, DH Kim, SA Lee, XF Yin, J Park, MY Lee, WB Lee, SH Lee, JK Kim, SS Kim, Y Jeong, SC Myung, TJ Kim, IJ Kang

Journal of medicinal food, **2016**, 19(3), 228‐237 | added to CENTRAL: 31 January 2017 | 2017 Issue 1

PubMed

42

[**Pelvic floor muscle training as a treatment approach for genitourinary syndrome of menopause**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01619936/full)

J Mercier, M Morin, D Zaki, B Reichetzer, M Lemieux, S Khalife, C Dumoulin

Neurourology and urodynamics, **2018**, 37, S265‐S266 | added to CENTRAL: 31 August 2018 | 2018 Issue 8

Embase

43

[**Glucocorticoid-induced osteoporosis**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01783367/full)

KG Saag

Endocrinology and metabolism clinics of North America, **2003**, 32(1), 135‐57, vii | added to CENTRAL: 31 March 2019 | 2019 Issue 3

PubMed Embase

44

[**A phase 2 randomized, double-blind Placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2-hormone receptor+ breast cancer patients (pts) with bone metastases (mets)**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01130356/full)

RE Coleman, L Huang, O Petrenciuc, P Zaccarini

Journal of clinical oncology, **2015**, 33(15) | added to CENTRAL: 29 February 2016 | 2016 Issue 2

Embase

45

[**CYP19A1 and ESR1 polymorphisms and selected early-onset side effects during combined endocrine therapy in the IBCSG TEXT trial for premenopausal women with hormone receptor-positive (HR+) early breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01100179/full)

H Johansson, KP Gray, O Pagani, MM Regan, G Viale, V Aristarco, D Macis, A Puccio, S Roux, R Maibach, M Colleoni, M Rabaglio-Poretti, AS Coates, RD Gelber, A Goldhirsch, R Kammler, B Bonanni, BA Walley

Cancer research, **2015**, 75(9) | added to CENTRAL: 30 November 2015 | 2015 Issue 11

Embase

46

[**Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: japanese Osteoporosis Intervention Trial-03**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01395886/full)

S Tanaka, T Miyazaki, Y Uemura, N Miyakawa, I Gorai, T Nakamura, M Fukunaga, Y Ohashi, H Ohta, S Mori, H Hagino, T Hosoi, T Sugimoto, E Itoi, H Orimo, M Shiraki

Journal of bone and mineral metabolism, **2017**, 35(4), 385‐395 | added to CENTRAL: 31 August 2017 | 2017 Issue 8

PubMed Embase

47

[**Role of stromal discoidin domain receptor-1 in breast cancer**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01377931/full)

K Gupta, B Yuan, R Li

Cancer research, **2017**, 77(4) | added to CENTRAL: 30 June 2017 | 2017 Issue 6

Embase

48

[**Updates from the MsFLASH Clinical Trials Network-A Panel Discussion**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02095237/full)

KA Guthrie, C Mitchell, S Srinivasan, SD Reed

Menopause (New York, N.Y.), **2019**, 26(12), 1453 | added to CENTRAL: 31 May 2020 | 2020 Issue 05

Embase

49

[**A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01749439/full)

HS Rugo, R Li, O Petrenciuc, A Zhang, RE Coleman

Journal of clinical oncology, **2016**, 34 | added to CENTRAL: 31 March 2019 | 2019 Issue 3

Embase

50

[**A Phase II Study of Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02706332/full)

O Danciu, N Chan, K Wisinski, T Millard, K Kemmer, S Phadke, Z Chen, AC Fernandez, M Clark, A Conlin, C Omene, S Ehsani, S Dublis, VK Gadi

Cancer research, **2024**, 84(9) | added to CENTRAL: 30 June 2024 | 2024 Issue 6

Embase

51

[**Assessing the humanistic burden of menopausal symptoms and estrogenprogestogen therapy side effects among postmenopausal women in the US**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01360236/full)

N Williamson, S Tatlock, R Arbuckle, L Abraham, M Moffatt, A Bushmakin

Menopause (New York, N.Y.), **2016**, 23(12), 1399 | added to CENTRAL: 31 May 2017 | 2017 Issue 5

Embase

52

[**A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2-hormone receptor1-breast cancer patients with bone metastases**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01749452/full)

RE Coleman, R Li, AG Sawhney, O Petrenciuc

Journal of clinical oncology, **2016**, 34 | added to CENTRAL: 31 March 2019 | 2019 Issue 3

Embase

53

[**A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01295786/full)

H Rugo, O Petrenciuc, A Zhang, R Li, RE Coleman

Annals of oncology, **2016**, 27 | added to CENTRAL: 28 February 2017 | 2017 Issue 2

Embase

54

[**Parathyroid hormone: an anabolic treatment for osteoporosis**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01762539/full)

P Morley, JF Whitfield, GE Willick

Current pharmaceutical design, **2001**, 7(8), 671‐687 | added to CENTRAL: 31 March 2019 | 2019 Issue 3

PubMed Embase

55

[**Effects of Korean red ginseng (Panax Ginseng Meyer) on bisphenol A exposure and gynecologic complaints: single blind, randomized clinical trial of efficacy and safety**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01114907/full)

M Yang, H-S Lee, M-W Hwang, M Jin

BMC complementary and alternative medicine, **2014**, 14(1) | added to CENTRAL: 31 January 2016 | 2016 Issue 1

Embase

56

[**Circulating 27-hydroxycholesterol and Risk of Colorectal Adenomas and Serrated Polyps**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02276083/full)

MN Passarelli, BM Thompson, JG McDonald, DC Snover, TJ Palys, JR Rees, EL Barry, JA Baron

Cancer prevention research (Philadelphia, Pa.), **2021**, 14(4), 479‐488 | added to CENTRAL: 30 June 2021 | 2021 Issue 06

PubMed Embase

57

[**Effect of Dietary Flaxseed Intake on Circulating Sex Hormone Levels among Postmenopausal Women: a Randomized Controlled Intervention Trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103116/full)

VC Chang, M Cotterchio, BA Boucher, DJA Jenkins, L Mirea, SE McCann, LU Thompson

Nutrition and cancer, **2019**, 71(3), 385‐398 | added to CENTRAL: 31 May 2020 | 2020 Issue 05

PubMed

58

[**A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate (ALN) on bone mineral density (BMD) and bone turnover in perimenopausal women with low BMD**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02216366/full)

Endocrine reviews, **2014**, 35(SUPPL. 3) | added to CENTRAL: 31 January 2021 | 2021 Issue 01

59

[**A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate (ALN) on bone mineral density (BMD) and bone turnover in perimenopausal women with low BMD**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01923945/full)

Endocrine reviews, **2014**, 35(SUPPL. 3) | added to CENTRAL: 30 April 2019 | 2019 Issue 04

60

[**Aspirin for the Prevention of Recurrent Venous Thromboembolism**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02018318/full)

NCT00222677

https://clinicaltrials.gov/show/NCT00222677, **2005** | added to CENTRAL: 31 January 2020 | 2020 Issue 01

CT.gov

61

[**The Effect of Metformin, an insulin-sensitizing drug, on Breast Cancer Primary Prevention: the Plotina Breast Cancer Prevention Randomized, Placebo Controlled Trial - PLOTINA**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01809910/full)

EUCTR2009-009921-28-IT

https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2009-009921-28-IT, **2010** | added to CENTRAL: 31 March 2019 | 2019 Issue 3

ICTRP

62

[**Prasterone**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01726521/full)

P Kocis

American journal of health-system pharmacy, **2006**, 63(22), 2201‐2210 | added to CENTRAL: 31 March 2019 | 2019 Issue 3

PubMed Embase

63

[**Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02373829/full)

F Sun, W Huang, J Chen, L Zhao, D Zhang, X Wang, W Wan, S-M Dai, S Chen, T Li, S Ye

Lupus science and medicine, **2022**, 9(1) | added to CENTRAL: 31 March 2022 | 2022 Issue 03

Embase

64

[**Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02495705/full)

A Vrselja, A Latifi, RJ Baber, BGA Stuckey, MG Walker, V Stearns, M Hickey, SR Davis

Lancet (london, england), **2022**, 400(10364), 1704‐1711 | added to CENTRAL: 30 November 2022 | 2022 Issue 11

PubMed

65

[**High Intensity Training in patients with rheumatoid arthritis**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01850142/full)

ISRCTN62313758

https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN62313758, **2008** | added to CENTRAL: 31 March 2019 | 2019 Issue 3

ICTRP

66

[**Comparison of osteoporosis pharmacotherapy fracture rates: analysis of a marketscan® claims database cohort**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01725971/full)

AW Reynolds, PT Kocis, G Liu, EJ Fox

Journal of orthopaedic research, **2016**, 34 | added to CENTRAL: 31 March 2019 | 2019 Issue 3

Embase

67

[**Effect of Genistein in Women With Metabolic Syndrome**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02020541/full)

NCT00541710

https://clinicaltrials.gov/show/NCT00541710, **2007** | added to CENTRAL: 31 January 2020 | 2020 Issue 01

CT.gov

68

[**The Relationship of Acupuncture Use to the Endometriosis Risk in Females With Rheumatoid Arthritis: real-World Evidence From Population-Based Health Claims**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02259695/full)

W-J Chen, H Livneh, C-H Hsu, Y-T Hu, N-S Lai, H-R Guo, T-Y Tsai

Frontiers in medicine, **2020**, 7 | added to CENTRAL: 31 May 2021 | 2021 Issue 05

Embase

69

[**Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01477765/full)

NCT00141908

https://clinicaltrials.gov/show/NCT00141908, **2005** | added to CENTRAL: 31 May 2018 | 2018 Issue 5

CT.gov

70

[**Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors- impact on breast adipose oxylipin and DNA methylation patterns**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02759973/full)

DE Frankhouser, T DeWess, IF Snodgrass, RM Cole, S Steck, D Thomas, C Kalu, MA Belury, SK Clinton, JW Newman, LD Yee

medRxiv: the preprint server for health sciences, **2024** | added to CENTRAL: 31 October 2024 | 2024 Issue 10

PubMed

71

[**Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors–impact on breast adipose oxylipin and DNA methylation patterns**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02776684/full)

DE Frankhouser, T DeWess, IF Snodgrass, RM Cole, S Steck, D Thomas, C Kalu, MA Belury, SK Clinton, JW Newman, LD Yee

medRxiv: the preprint server for health sciences, **2024** | added to CENTRAL: 30 November 2024 | 2024 Issue 11

Embase

72

[**Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: a Randomized Clinical Trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02751224/full)

Y You, Z Zhou, F Wang, J Li, H Liu, X Cheng, Y Su, X Chen, H Zheng, Y Sun, H Shi, Q Hu, J Xu, J Teng, C Yang, J Ye

JAMA network open, **2024**, 7(9), e2432131 | added to CENTRAL: 30 September 2024 | 2024 Issue 9

PubMed

73

[**A Study to Evaluate the Continuous Safety and Efficacy of BIIB059 in Adults with Active Systemic Lupus Erythematosus**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02518402/full)

EUCTR2021-006378-22-NL

https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-006378-22-NL, **2022** | added to CENTRAL: 28 February 2023 | 2023 Issue 2

ICTRP

74

[**The Effect of Vagus Nerve Stimulation on Temporomandibular Joint Dysfunction**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02471205/full)

NCT05500716

https://clinicaltrials.gov/ct2/show/NCT05500716, **2022** | added to CENTRAL: 31 October 2022 | 2022 Issue 10

CT.gov

75

[**Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus Nephritis**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02734528/full)

NCT06485648

https://clinicaltrials.gov/ct2/show/NCT06485648, **2024** | added to CENTRAL: 31 August 2024 | 2024 Issue 8

CT.gov

76

[**Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180583/full)

NCT04389580

https://clinicaltrials.gov/show/NCT04389580, **2020** | added to CENTRAL: 31 October 2020 | 2020 Issue 10

CT.gov

77

[**Comparison of Sacrospinous Ligament Fixation and Uterosacral Ligament Suspension for Apical Prolapse Surgery: a Randomized Clinical Trial**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02509954/full)

NCT05668130

https://clinicaltrials.gov/show/NCT05668130, **2022** | added to CENTRAL: 31 January 2023 | 2023 Issue 1

CT.gov

78

[**Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)**](https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103277/full)

NCT04353180

https://clinicaltrials.gov/show/NCT04353180, **2020** | added to CENTRAL: 31 May 2020 | 2020 Issue 05

CT.gov